Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 32

Total 32 documents found.

  •  
  • Building Toward Leadership in Oncology Deborah Dunsire, MD President and Chief Executive Officer, Millennium: The Takeda Oncology Company Disclaimer This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All f d l ki t t t b d j d t d i d f th i f ti il bl t thAll forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward-looking statements can sometimes be identified by the use of forwardlooking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target," "forecast," "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward-looking statements contained in this presentation. These risks and uncertainties include, but are not limited to: (1) the
  • SUMMARY OF FINANCIAL STATEMENTS [Japan GAAP] (CONSOLIDATED) Financial Results for the First Quarter (April 1 to June 30, 2010) of the Fiscal Year Ending March 31, 2011 July 30, 2010 Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of securities report submission: August 10, 2010 Scheduled date of dividend payment commencement: Supplementary materials for the quarterly financial statements: Yes Presentation to explain for the quarterly financial statements: Yes (Millions of yen, rounded to the nearest million) 1. Consolidated Financial Results (April 1 to June 30, 2010) for the Fiscal Year Ending March 31, 2011 (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of t
  • Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with alpha-GI) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Concomitant therapy with Sulfonylurea) Diabetes mellitus (Concomitant therapy with Biguanide) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn EU Jpn Jpn Jpn Jpn US EU FDA Complete Response Letter (Jun 09) Approved (Apr 10) P-III FDA Complete Response Letter (Sep 09) Filed (Jun 09) P-III Approved (Apr 10) Filed (Jun 09) Filed (Mar 10) Filed (Mar 10) P-III P-III In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Jpn EU Approved (Apr 10) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-es
  • Recent Achievement Deals
  • This section describes the records of Takeda's successful alliances with various partners, ranging from global pharmaceutical companies to relatively smaller firms.
  • FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • 36 Enhancement of the R&D Pipeline through In-Licensing and Alliance Activities R&D Alliance Note: Established in 2002, Teijin Pharma Limited is the core company of Teijin Group's medical and pharmaceuticals business. Its main businesses are in pharmaceuticals and delivery of home healthcare services. It specializes in the development of innovative products and services in the three fields of bone and joint diseases. respiratory disease, and metabolic and cardiovascular disease. Partner's Voice Takeda is a Japanese company that has enjoyed considerable international success. In 1999, we entered into a licensing agreement with Takeda's U.S. subsidiary TPNA for ULORIC (generic name: febuxostat), a treatment for hyperuricemia in patients with gout. I have since been deeply impressed with Takeda's superb development capabilities and their attitude in constantly rising to the challenge of overcoming numerous obstacles. All these efforts have now paid off, and I am delighted that the product was launched in the U.
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (CONSOLIDATED) Financial Results for the Fiscal Year Ended March 31, 2010 May 12, 2010 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki, Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2010 Scheduled date of securities report submission: June 25, 2010 Scheduled date of dividend payment commencement: June 28, 2010 (Millions of yen, rounded to the nearest million) 1. Consolidated Results for Fiscal 2009 (April 1, 2009-March 31, 2010) (1) Consolidated Operating Results (Percentage figures represent changes from same period of previous
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction Whole of the pharmaceutical industry has tendency to face a number of challenges, such as stagnation in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace, and increasingly strict criteria for the approval of new drugs in advanced countries. Drastic changes in the healthcare systems are underway in many countries, by which it is anticipated that the pharmaceutical industry will be considerably affected. First of all, in the U.S., a bill of healthcare reform which aims to increase the ratio of the insured population was passed. Under the bill, pharmaceutical companies are requested to bear the burden of some portion of funds in order to finance the expansion of available health insurance by increase of the number of po
  • Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis May 26, 2009
  • May 26, 2009, Osaka, Japan --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it entered into agreement with Novartis (Switzerland, “Novartis”) for vaccine for prevention of infection caused by Haemophilus Influenzae Type B (“Hib”). Novartis has developed that vaccine, known as “Vaxem Hib®”, by combining it with detoxified diphtheria toxin in order to increase immunogenicity, assuring the potential to induce the production of antibody in infants.
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
  • Appointment of New CEO of Takeda Pharmaceuticals Asia Private Limited January 13, 2009
  • Osaka, Japan, January 13, 2009 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the appointment of Mr. Stefan Ziegler as CEO of Takeda Pharmaceuticals Asia Private Limited (“TPAsia”), its wholly owned subsidiary for oversight of overall Asian sales and marketing. Mr. Ziegler received a bachelor’s degree in Business administration with major in Finance and Marketing at University of Zurich in Switzerland and worked at Novartis from 1990 to 2008.
  • Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics May 27, 2008
  • CAMBRIDGE, Mass., USA and OSAKA, Japan, May 27, 2008 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This landmark alliance is the first major RNAi therapeutics partnership between a Japanese pharmaceutical company and a U.S. biotechnology company, representing a new frontier in the advancement of RNAi therapeutics to patients on a global basis.
  • European EMEA acceptance of Marketing Authorization Application filing for SNT-MC17 in Friedreich’s Ataxia by Santhera August 17, 2007
  • Liestal, Switzerland and Osaka, Japan, August 16, 2007 – Santhera Pharmaceuticals (SWX: SANN, “Santhera”), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, and Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”), jointly announced today that the European Medicines Agency (EMEA) has accepted the filing of Marketing Authorization Application (MAA) for Santhera’s lead compound SNT-MC17 (INN: idebenone, originally developed by Takeda) for the treatment of Friedreich’s Ataxia (FRDA). SNT-MC17, which has been granted orphan drug designation in the EU, could become the first approved product for the treatment of FRDA and will be marketed in Europe by Santhera’s partner Takeda. SNT-MC17 has shown clinical efficacy in FRDA patients on neurological as well as cardiac endpoints in several clinical studies and proved to be well tolerated in all studies so far.
  • XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development February 28, 2007
  • Berkeley, CA, and Osaka, JAPAN - February 28, 2007 - XOMA Ltd. (Nasdaq: XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006.With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has receivedor is otherwise due approximately $8 million as various collaboration-related payments.
  • CEO of a New Company for European Operations Appointed December 5, 2006
  • Osaka, Japan, December 5, 2006 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that, on December 1, Mr. Giacomo Di Nepi joined Takeda as CEO of the new company for Takeda European Operations, Takeda Pharmaceuticals Europe Limited ("TPEU"), which was established as a wholly owned subsidiary in last August and is now starting its activities.

Pages:[1] [2]   Next

Page Top